2026-04-17T17:17:38Zhttps://recercat.cat/oai/requestoai:recercat.cat:2072/4733992025-09-22T07:13:02Zcom_2072_98col_2072_378192
urn:hdl:2072/473399
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : A retrospective analysis of the EBMT chronic malignancies working party
Scheid, Christof
de Wreede, Liesbeth C
Van Biezen, A.
Koenecke, C.
Göhring, G.
Volin, L.
Maertens, J.
Finke, Juergen
Passweg, J.
Beelen, Dietrich
Cornelissen, J. J.
Itälä-Remes, Maija
Chevallier, P.
Russell, N.
Petersen, E.
Milpied, N.
Richard Espiga, C.
Peniket, A.
Sierra Llopart, Jordi
Mufti, G.
Crawley, C.
Veelken, J.H.
Ljungman, P.
Cahn, Jean-Yves
Alessandrino, E.P.
de Witte, Theo
Robin, M.
Kröger, N.
Universitat Autònoma de Barcelona
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (Po0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (Po0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.
2017
Article
Bone marrow transplantation ; Vol. 52 Núm. 11 (january 2017), p. 1519-1525
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
https://creativecommons.org/licenses/by-nc-nd/4.0/